hVIVO signs £6.8m RSV contract with second APAC client

hVIVO plc (LON:HVO), (formerly Open Orphan plc) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that it has signed a £6.8m contract with a leading pharmaceutical company based in Asia Pacific, to test its respiratory syncytial virus antiviral drug candidate, using the hVIVO RSV Human Challenge Study Model.

The Phase 2a double-blinded placebo-controlled human challenge trial will take place at the Company’s specialist quarantine facilities in Whitechapel and will evaluate the efficacy profile of the antiviral against RSV infection in healthy volunteers. The study is expected to commence in H1 2024, with revenue mostly recognised in 2024. As part of the study, hVIVO will recruit healthy volunteers via the Company’s dedicated volunteer recruitment arm, FluCamp.

RSV is the main cause of childhood lower respiratory infections and is responsible for a significant burden of disease in the elderly and in adults with chronic medical problems, such as COPD. Globally it affects an estimated 50 million people annually, leading to four million hospitalisations and approximately 60,000 in-hospital deaths in children younger than five years.1 hVIVO has inoculated over 1,600 healthy volunteers across 28 RSV challenge trials to date and the challenge trial data has already expedited the development of several RSV vaccines for a number of pharmaceutical companies.

This is the second human challenge trial contract that hVIVO has signed with an Asia-Pacific client in 2023 following the identification of this region as a key growth area for the Company. The strength of data generated from hVIVO’s human challenge trials is resulting in a growing demand from global biopharmaceutical companies, as they seek to de-risk their development programmes ahead of later stage field studies.

Yamin ‘Mo’ Khan, Chief Executive Officer of hVIVO, said: “We are delighted to be working with this client on their important RSV programme. RSV has been a particular blight on humanity with no effective vaccine against this virus in over 60 years of R&D. Our RSV challenge trial model is a tried and tested model that has been used to expedite the development of several RSV vaccine candidates, and we expect that at least one of the vaccines we have worked on will reach patients this year. This new client will benefit from our experience and expertise to impact their drug development plans.

“For hVIVO, it is highly encouraging to see our global client list continue to grow and our orderbook further diversify with our second significant contract with an APAC client. One of our goals for 2023 is to attract more customers from the APAC region, and we have already seen this come to fruition with two contracts. It is a great start to the year and builds our pipeline for 2024. We expect to continue this strong momentum in the APAC region, and the rest of the world, as the growing number of biopharma companies recognise the strong value of human challenge models.”

1 Shi, T. et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. The Lancet 390, 946-958 (2017).

Click to view all articles for the EPIC:
Or click to view the full company profile:
    hVIVO plc

    More articles like this

    hVIVO plc

    Clinical Trial participation and eligibility requirements

    People who haven’t had the opportunity to participate in a clinical trial often wonder about eligibility criteria. Each trial has its own goals and purposes, so the inclusion criteria vary. Many trials require participants with specific

    hVIVO plc

    A complete guide to Clinical Trials

    Clinical trials play a vital role in the discovery, testing, and eventual marketing of new drugs. Over a million individuals participated in clinical trials during 2022/23, involving more than 6,000 studies. Understanding eligibility criteria for clinical

    hVIVO plc

    Importance of Clinical Trials in the medical industry

    Clinical trials play an important role in helping to ensure new drugs can be discovered, tested for safety and efficacy, and ultimately make their way onto the market. Over a million people took part in clinical trials during

    hVIVO plc

    European Mediscience Awards 2024 shortlist announced

    The European Mediscience Awards is now in its 22nd year, having been held every year since inception in 2002*. The event is the largest annual gathering of private and publicly quoted healthcare, biotech and life sciences companies in Europe.

    hVIVO plc

    Hvivo expects Continued Growth with Record Year in 2023

    Hvivo, a pharmaceutical services company formerly known as Open Orphan, said it remained on track to hit its future growth targets after another record year in 2023. The company is set to begin paying annual dividends,

    hVIVO plc

    hVIVO to hold AGM on 13 May 2024

    hVIVO plc (LON:HVO), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has confirmed that the Company’s Annual Report and Accounts for the year ended

    hVIVO plc

    Hvivo reports 44% Rise in earnings and Record Year in 2023

    Pharmaceutical services firm Hvivo, formerly Open Orphan, reported a 44pc rise in earnings in 2023 in a “record year across all financial and operational metrics.” Earnings before interest, taxes, depreciation and amortisation (Ebitda) increased to £13m

    hVIVO plc

    hVIVO Investor Conference

    hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials,